Surntnary CD4 T cell receptors (TCRs) recognize antigenic peptides presented by self major histocompatibility complex (MHC) class II molecules as well as non-self MHC class II molecules. The TCR.s can also recognize endogenous retroviral gene products and bacterial toxins known collectively as superantigens (SAGs) that act mainly on the V{3 gene segment-encoded portion of the V{3 domain; most SAGs also require MHC class II for presentation. We have studied the interaction of the TCR from a well-characterized CD4 T cell line with SAGs by mutational analysis of its VI3 domain. This appears to separate viral (v)SAG from bacterial (b)SAG recognition. T cells having a TCR. with a glycine to valine mutation in amino acid residue 51 (G51V) in complementarity determining region 2 of the TCIL V[3 domain fail to respond the bSAGs staphylococcal entertoxin B (SEB), SEC1, SEC2, and SEC3, whereas they retain the ability to respond to non-self MHC class II molecules and to foreign peptides presented by self MHC class II molecules. It is interesting to note that T cells expressing mutations of both G51V and G53D of V[3 regain the response to SEB and partially that to SEC1, but do not respond to SEC2 and SEC3, suggesting that different bacterial SAGs are viewed differently by the same TCR. These results are surprising, because it has been generally believed that SAG recognition by T cells is mediated exclusively by hypervariable region 4 on the exposed, lateral face of the TCR V[3 domain. Response to the vSAG Mtv-7 was generated by mutation in V[3 residue 24 (N24H), confirming previously published data. These data show that the vSAG Mtv-7 and bSAGs are recognized by different regions of the TCR V[3 domain. In addition, various bSAGs are recognized differently by the same TC1L. Thus, these mutational data, combined with the crystal structure of the TCR ~3 chain, provide evidence for distinct recognition sites for vSAG and bSAG.
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The TC1L can recognize superantigens (SAGs) derived .IL from bacterial or endogenous retroviral genes (bSAG or vSAG). Unlike conventional antigen recognition, where the CDR3 regions of the TCR ~ and [3 chains play a critical role, response to these substances involves primarily the V[3 gene segment-encoded portion of the V[3 domain of the TCR. As 2-10% ofT cells express the product of a given V[3 gene segment, SAGs stimulate T cells of many different specificities. Recognition ofbSAGs and vSAGs by the TCR is believed to involve regions distinct from the antigen recognition site, comprising the CD1L 1, 2, and 3 loops of both chains of the TCR, as predicted earlier (1) . Many reports have shown that a region known as hypervariable region 4 (HVR4) between the E and F strands of the TCR. V[3 domain is a crucial site for SAG recognition, but is not 1Abbreviations used in this paper: bSAG, bacterial superantigen; CA, conalbumin; HVR4, hypervariable region 4; SAG, superantigens; SEB, Staphyloccal enterotoxin B; TSST-1, toxic shock syndrome toxin 1. involved in responses to foreign peptide-.self MHC (2) (3) (4) . Although several reports (5) (6) (7) (8) suggest that TCI~ sites other than the HV1L4 of the TCR V[3 domain affect recognition of SAGs, all of these studies nevertheless point to the lateral face of V[3 as the most crucial factor in SAG recognition. Recently, the x-ray crystal structure of the bSAG Staphylococcal enterotoxin B (SEB) bound to the human MHC class II HLA-DR1 molecule has been solved (9) . This shows that SEB binds to the or-helical region of the HLA-DR ot chain; if the TCR V[3 domain recognizes this complex, the TCR Voc domain must sit on top of the or-helical region of the HLA-DR [3 chain. In fact, two studies showed that the V region of the TCR ct chain interacts with the or-helical region of the HLA-DR [3 chain during SEB recognition (10, 11) . Previously, we have reported that during non-self MHC recognition, the CDR1 and/or CDR2 of the TCR Vet domain interacts with the or-helical region of the I-A ot chain, leading us to conclude that the TCR [3 chain must interact with the I-A [3 chain (12) . This TCtL-MHC inter-action appears to be in a distinct orientation from the TCK-SEB--MHC interaction.
In this report, we have examined SAG recognition by the TCtL of the well-characterized CD4 T cell line D10.G4.1 (13) . We have examined the role of several amino acid residues, including those in the CDR1 and CDR2 equivalents of the TCR [3 chain, in recognition of both bSAG and the vSAG Mtv-7, as well as in recognition of foreign peptide-self MHC and non-self MHC class II molecules. One mutation at residue 51 from glycine to valine (G51V) in CD1L2 of the TCK V~3 domain, which does not affect non-self MHC recognition, has a profound effect on responses to the bSAGs SEB, SEC1, SEC2, and SEC3. It is interesting to note that T cells expressing this mutation plus that of a neighboring residue (D 10etG51V,G53D [3) , recover responsiveness to SEB and SEC1, but not to SEC2 and SEC3, whereas cells having D10etG53DI$ respond well to all bSAGs. In agreement with the earlier studies (2), a mutation at residue 24 (N24H) of the TCK [3 chain results in a gain of response to the vSAG Mtv-7. Tranffectants expressing mutations in both Vet and VI3 retain the characteristic responses of each chain when stimulated separately either with non-self MHC molecules or with SAG.
Materials and Methods
Animals. The mice used in these studies were obtained from
The Jackson Laboratory (Bar Harbor, ME) or from the Core Mouse Breeding Facility maintained at Yale. The following mouse strains were used: B10.BI~ (I-Ak), AKK/J (H-2 k, Mls-la), and C57BL/6J
(I-^b).
Antibodies. The following mAbs were used: monoclonal antiCD3e YCD3-1 (14) and monoclonal anti-CD4 GK1.5 (15) . Cell Lines. The T cell line D10.G4.1 (13) has been described previously. The class II MHC-expressing cell line CH27 has been described previously (16) . The 4G4, TCIL 0t and 13 negative T cell hybridoma was kindly provided by Ed Palmer (Basel Institute for Immunology, Switzerland). This cell line allows expression of transfected ct/13 heterodimeric TCR. Mutagenesis of TCR ~ Chain. Mutagenesis of a TCK 13 chain cDNA construct was performed using the overlapping extension method (17) with the PCK. PCK conditions were 25 cycles of 1 min at 94~ 1 rain at 55~ and 2 rain at 72~ using wild-type D10 TCtL 13 chain cDNA as a template DNA. The following PCK primers were used. 5' primer GTATCCTGA-GAGGAAGCATG and 3' primer CTGCTCGGCCCCAGGCC-TCT were the two external primers to generate the mutation. Mutagenic primers were as follows: N24H, coding sequence, GAGCTGTCACCAGACTAATA, noncoding sequence, TAT-TAGTCTGGTGACAGCTC; H29E, coding sequence, TGTAAT-CAGACTAATAACGAGAACAACATG, noncoding sequence, CATGTTGTTCTCGTTATTAGTCTGATTACA; G51V, coding sequence, CATTATTCATATGTTGCTGC~AGCACT, noncoding sequence, AGTACTGCCAGCAACATATGAATAATG; G53D, coding sequence, TCATATGGTGCTGACAGCACT-GAGAAA, noncoding sequence, TTTCTCAGTGCTGTCAG-CACCATATGA; and G51V/G53D, coding sequence, CATTAT-TCATATGTTGCTGACAGCACTGAG, noncoding sequence, CTCAGTGCTGTCAGCAACATATGAATAATG. Production and Analysis of Transfectants. Transfected T cell hybridomas expressing mutant VI38.2 chains were generated and analyzed as previously described (12) . Peptides and SAGs. Peptides were synthesized as described (18 (19, 20) and the bSAGs SEB, SEC1, SEC2, and SEC3 (1). In an earlier study, we showed that the NH2-terminal half of the TCR Vet domain played a critical role in the recognition ofnon-selfMHC class II I-A molecules (12) . These studies suggested that the CDK1 and/or CDR2 equivalent of the Vet domain interacts with the a-helical region of the I-A et chain. We have identified Vet residue 30 as the primary distinction between these two TCR. molecules (Hong, S.-C., D.B. Sant'Angelo, G. Waterbury, and C.A. Janeway, Jr., manuscript submitted for publication).
To further analyze the individual amino acids responsible for the recognition of SAGs, we initiated a mutational analysis of the D10 TCR V[3 domain. The V domain of the 13 chain of the D10 TCR is encoded by V [38.2 (12) . Because mice have three closely related V[38 genes, we used the nine amino acid differences between TCR VI38.1 and TCR. VI38.2 to guide our mutagenesis strategy. These differences are located between the NHz terminus and CDK1, in CDK1 residues 30 and 31, in CDR2 residues 51 and 53, and in strand F between CDR.2 and CDR.3 ( Table 1 ). The majority of T cells expressing TCK V[38.1 recognize a vSAG, Mtv-7, whereas only a small fraction of T cells expressing TCK V[38.2 do so (2, 21) . On the other hand, SEB strongly stimulates T cells expressing VI38.2 but only weakly stimulates T cells expressing TCR. V[38.1. It is known that the CD1L3 regions of both Vet and VI3 are involved in peptide recognition (12, (22) (23) (24) . Moreover, as CDR3 is thought to lie in the center of the TCR. recogni- 
A S tion site, mutations in C D R 3 are not informative as to SAG recognition (data not shown). W e have therefore focused our analysis on mutagenesis of C D R 1 and C D R 2 o f the T C R VJ3 domain. Several independent mutations were generated by overlapping P C R mutagenesis (17) . The wildtype and mutant D10 T C R ]3 chain cDNAs were cotransfected with D10 T C R ix chain c D N A as well as mouse CD4 c D N A into a routine hybrid thymoma called 4G4. These transfectants expressed comparable levels o f the T C R and CD4 molecules as detected by FACS | analysis ( Table  2) . All the transfectants were tested for their response to a n t i -T C R or anti-CD3 mAb, to antigen presented by self M H C , to allogeneic M H C molecules, and to both bSAG and vSAG.
vSA G Mtv-7 Is Recognized by Residue 24 which Contributes to H V R 4 of the T C R V~ Domain.
According to the crystal structure o f the T C R VJ38.2 chain (25), residue 24 o f the T C R J3 chain is adjacent to the H V R 4 loop, and is exposed on the lateral surface ofV[38.2 together with two adjacent amino acids in H V R 4 , 73 and 74, that are known to affect Mtv-7 recognition (Fig. 1 a) (2) . W h e n asparagine (Fig. 2 a) . As expected, cells bearing the TCR D10otN24H[3 responded strongly to antigen, to SEB, and to allogeneic MHC molecules (Fig. 2 , b-d). These data confirm that recognition of the vSAG, Mtv-7, is mediated by the lateral face of HVR4 of the TCR V[3 domain.
Effect of Amino Acids in the CDR2 Loop of the TCR Vfl Domain on Recognition of bSA G. When T cells expressing
various mutations in TCR. V[38.2 were tested for their responses to the bSAG, SEB, all T cells except those with a mutation in CDR2 residue 51 (D10otG51VI3) responded equally to SEB (Fig. 3 a) . Cells bearing D10otG51V~ responded to anti-CD3 mAb stimulation and to allogeneic MHC molecules equivalently to D10otD10[3 transfectants, but showed a diminished sensitivity to antigenic peptide (Fig.  3, b-d) . We also tested other bSAGs that are recognized by the murine TCR V[38.2. As expected, all of these bSAGs stimulated transfectants expressing D10otD10~, but none stimulated transfectants expressing the mutant D10otG51V [3; this suggests that all of these recognition events are affected by this mutation (Fig. 3, e-g ). We also tested many other T cells expressing other mutant TCR [3 chains, and all of these responded to SEB as well as to anti-CD3 mAb stimulation, with the exception of those having the G51V[3 mutation (Table 2) .
To further analyze this loss of function mutation, T cells expressing [3 chains with double mutations, including G51V[3, were produced. T cells expressing the double mutations N24H,G51V[3, and H29E,G51V[3, together with the D10 TCR ot chain, responded well to anti-CD3 mAb stimulation (Fig. 4 a) , but failed to respond to stimulation with SEB (Fig. 4 b) . This again confirms the role of G51V[3 in SEB recognition. In addition, T cells expressing N24H, G51V[3 responded well to Mtv-7 (Fig. 4 c) , segregating vSAG and bSAG recognition by the same TCR V[3 domain.
Differences in the Recognition of bSAGs by the Same TCR.
T cells expressing the mutation G51V[3 lost response to all the bSAGs tested (Figs. 3 and 4) , whereas additional mutations in other residues in V[3, such as the [3 strand-associated N24H,G51VI3 and the CDP,1 loop H29E, G51V[3 did not alter responses to SEB from those observed with the original G51V~ mutation. However, when T cells express- ing a double mutation in CDR2, replacing residues 51 and 53 with those naturally found in inbred TCR V138.1 (G51V,G53DI3), the resulting transfectants (D10~G51V, G53D [3) were found to have recovered responses to SEB and to high concentrations of SEC1, but not those to SEC2 and SEC3 (Fig. 5) . These data again demonstrate that the CDR2 loop affects the recognition of all of these bSAGs and that SEB and the SECs are recognized similarly, but not identically, by this TCR.
Responses to Allogeneic MHC Class II Molecules and to bSAG Are Independent Recognition Events by the Same TCR.
We tested whether the TCR recognizes MHC class II molecules in the same way during responses to allogeneic MHC class II molecules and to bSAG. To do so, we made a transfectant that expresses a well-characterized mutant TCR et and 13 chain. The TCR, AK8:D10aD10[3, contains seven mutations in the NH2-terminal half of the TCR ~x chain that result in a gain of response to I-A d and a loss of response to I-A b from the original wild-type D10otD1013 TCR (12) . We made a transfectant expressing this TCR cx chain paired with a [3 chain containing the G51V mutation, and tested its reactivity. This T cell, called AK8:D10otG51V [3, did not respond to SEB, which is characteristic of the TCR [3 chain mutation G51V[3, but maintained its response to anti-CD3 mAb (Fig. 6, a and b) . In addition, this double mutant TCR lost its usual response to I-A b and gained a response to I-A d, which is characteristic of the mutant TCR ~x chain AK8:D10ot (Fig. 6, c and d ). This suggests that TCR recognition ofallogeneic MHC molecules and bSAG can occur independently. 
Discussion
The TCR of the CD4 T cell clone D10.G4.1 recognizes a peptide fragment of antigen presented by self MHC class II molecules, allogeneic MHC class II molecules, and vSAG and bSAG presented by self MHC class II molecules. In this study, we made site-directed mutations of the V[3 domain in an attempt to understand the nature of these various TCR-ligand interactions. We have shown for each mutant tested in this manuscript, a retention of normal or slightly decreased recognition of peptide plus self MHC class II and/or of aUogeneic MHC class II. Thus, we believe that the mutations we have introduced do not significantly perturb MHC class II recognition by this receptor. Although the resolution of a crystal structure of this receptor-ligand pair should provide major insights into this crucial process, the variability of both the TCR and its ligands, and the complexity of signaling through the receptor, require detailed functional analysis of this interaction as well. Moreover, the low affinity of TCR-ligand interactions (26, 27) suggests that obtaining such complexes may be extremely difficult; indeed, it has been suggested (28-30) that binding of the TCR alone is not sufficient for T cell activation, and that a conformational change in the TCR may occur as an essential part of recognition. If this is the case, then crystallographic analysis may be even more difficult. Therefore, we have approached this problem by making a detailed structure-function analysis of this interaction an alternative approach. We have made several TCR mutations in both Vex and V13 of the D10 TCR to try to determine which residues mediate each interaction of the TCR with its various MHC class II ligands. Since the Va and V[3 CDR3 loops of the TCR are said to interact with different residues of a foreign peptide presented by selfMHC molecules, the information acquired by CDR3 mutation may be limited to the interaction of the TCR with specific antigen (22) . To understand TCR-MHC and TCR-SAG interactions, we and others (2, 3, 12, 31, 32) have used mutational studies of CDR1, CDR2, and HVR4, each of which defines a loop of the o~ and 13 chains of the TCR. Here, we will discuss how our new data may further the understanding of this interaction.
TCR recognition of SAG has been well characterized. Because of the polyclonal in vivo deletion of T cells expressing certain V[3 chains in mice expressing endogenous vSAG and the polyclonal expansion of the same T cells by vSAG and bSAG in vitro and in vivo (33) , this recognition event is believed to be mediated by specific polymorphic sites in the V13 gene segment-encoded part of the 13 chain. Mutational and transfection studies of TCR support the V13-mediated recognition of SAG, especially the role of HVR4 in the TCR V13 domain (2) (3) (4) . We have confirmed the finding reported by PuUen et al. (2) that mutation in residue 24 (here, N24H) in the V~ domain can confer Mtv-7 reactivity on a V~8.2 TCR. It is clear from the crystal structure of the TCR V~8.2 chain (Fig. 1, a and b ) that amino acid residue 24 on the lateral face of V~ associates with residues 73 and 74 which are known to be involved in Mtv-7 recognition. In addition, these three amino acid residues are located away from the peptide-MHC interaction site. This may facilitate the direct interaction of Mtv-7 with this site, as predicted (1) . Glycosylation of asparagine residues 24 and 74 may interfere with the interaction of wildtype TCR V[38.2 with Mtv-7. Substitution of one of these two asparagine residues seems to be sufficient for Mtv-7 interaction, since mutation of amino acid residue 74 from asparagine to glutamic acid also restores Mtv-7 reactivity (2). Our data on the role of residue 51 of CDR213, shown by the mutant G51V, support other studies for TCR recognition ofbSAG (31, 32) that describe evidence that CDR1 or CDR2 of the TCR V[3 chain can affect bSAG recognition. The crystal structure of the TCR V[~8.2 chain (Fig. 1, a  and b) clearly demonstrates that amino acid residue 51 is distant from the amino acids critical for a response to Mtv-7. In addition, this amino acid, which is facing towards the peptide-MHC, is not carried on the lateral face of V~ like the Mtv-7-binding site. Recent crystal structures of SEB bound to HLA-DR1 (9) and of toxic shock syndrome toxin-1 (TSST-1) bound to HLA-DR1 (34) show that SEB contacts HLA-DR1 at two sites on the DR1 c~ chain along one edge of the peptide-binding groove. The TSST-1-binding site, on the other hand, extends over almost half of the peptide-binding site, so that TSST-1 contacts the cl-helical region of the DR1 ot chain, the bound peptide, and part of the o~ helix of the DR1 ~ chain. This suggests that TSST-1 binding may be peptide dependent. Furthermore, it is likely that the recognition of TSST-1-DR1 by the TCR is very different from that of SEB-DR1 or peptide-DR1. Both of these crystal structures suggest that bSAG recognition by the TCR may be mediated by either CDR1 or CDR2 of the TCR, rather than the lateral part (HVR4) of the TCR, as has been shown in responses to the vSAG Mtv-7.
T cells expressing the double mutation N24H~ and G51V~ provide further evidence for the separation ofvSAG and bSAG recognition by one TCR. In contrast to the wildtype D10 TCR, which responds to many bSAGs including SEB, D10otG51V[3 does not respond to these bSAGs. On the other hand, T cells expressing the double mutation D10otN24H,G51V[3 gain a response to the vSAG Mtv-7, without gaining response to SEB. These data are in agreement with the data of Patten et al. (31) and BeUio et al. (32) regarding bSAG recognition, and with the data ofPullen et al. (2) and Cazenave et al. (4) regarding vSAG recognition. In addition, Thibodeau et al. (35) showed that binding sites for vSAGs and bSAGs are different in MHC class II molecules, suggesting two independent SAG recogntion sites on the TCR.
There are many reports that show that different bSAGs (e.g., TSST-1, SEA, SEB) bind to different regions of the MHC class II molecule (36) (37) (38) (39) . Since all of these SAGs are recognized by various TCR V~ domains, they are likely to be recognized in many different TCR-MHC orientations. Thus, it is not reasonable to expect that a general orientation of the TCR to its MHC-peptide ligand can be deduced from responses to bSAGs. It has also been shown that different mutant MHC molecules affect antigen presentation and presentation of the bSAG, SEA, to T cells differently (40) .
Recently, Hamad et al. (41) showed that SEB presented by a plate-bound anti-SEB mAb can stimulate T cells in the absence of MHC class II molecules. In addition, a Bia-core | binding study by Seth et al. (42) suggests direct TCR-SEB interaction. Some bSAGs, such as SEC and SEE, can stimulate T cells using MHC class II-negative APCs (43) . All these data suggest that bSAG can directly stimulate the T cell without need of a direct interaction of the TCR. with MHC class II molecules. By contrast, no comparable observations on binding of Mtv-7 have been obtained (44) .
In conclusion, our studies show that residue 24 of the TCR, [3 chain accounts for a contact with the vSAG encoded by Mtv-7. In addition, we find that mutations in CDR2 of V [3, especially that at residue 51, disrupt SEB recognition without affecting responses to the vSAG Mtv-7 or alloantigen recognition. It is perhaps most surprising that the double mutant of V[3, G51V,G53D, responds to SEB and to high doses of SEC1, but still lacks a response to SEC2 and SEC3. In addition, a transfectant expressing a single amino acid mutation in V[3, G53D, responds better than wild-type to SEB and SEC1, and responds normally to SEC2 and SEC3 (Fig. 5) . Thus, whereas we can make a model for bSAG interaction with this TCR, it is clear that this model will have to be complex.
